Resistance to trastuzumab and other tyrosine kinase inhibitors in ERBB2+ breast and lung cancer is a grand challenge that needs to be overcome to improve clinical outcomes and to prevent drug resistance and help sufferers of these deadly cancers. This evidence concerns the gene ERBB2 and lung cancer.